Technical Data
Polyethylene Glycol (PEG)
Polyethylene glycol PEG is a family of long chain polymers attached to a glycerine backbone. It is a nonionic, nontoxic, biocompatible, strongly hydrophilic polymer, which has a large exclusion volume in aqueous solution (1). The covalent attachment of PEG is now commonly used to modify a variety of proteins and drugs (2,3). The modification of a biopharmaceutical with polyethylene glycol (PEG) increases its hydrodynamic radius, reduces immunogenicity and proteolytic cleavage. Other benefits include decelerated renal excretion, improved stability towards proteolysis and increased solubility of the biopharmaceutical in aqueous solutions (4). As examples, PEG-adenosine deaminase (Adagen®) is used for the treatment of severe combined immunodeficiency syndrome, PEG–asparaginase (Oncaspar®) is used for the treatment acute lymphoblastic leukemia, PEG–interferon alpha-2a (Pegasys®) is used for the treatment Hepatitis C, Branched PEG–anti-VEGF aptamer (Pegaptanib, Macugen™) is used for the treatment Macular degeneration(age-related) (5). An anti-PEG antibody can be used to monitor a drug’s pharmacokinetics, including distribution, metabolism and excretion. In addition, it can be used for the quality control of pegylated molecules in ELISA, Western Blot and Flow Cytometry. In both direct and sandwich ELISA assays, P4444-27 shows greater affinity and accuracy than other PEG antibodies when determining the concentration of PEG or PEG-modified proteins. Results were similar whether detecting PEG itself or PEG-modified targets.

Suitable for use in ELISA, Immunohistochemistry and Western Blot. Other applications not tested.

Recommended Dilutions:
ELISA: 5-10ug/ml
Western Blot: 0.2-1ug/ml
Immunohistochemistry (Paraffin): 1-5ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Manufactured incorporating RabMAb® technology under Epitomics US patents, No 5,675,063 and 7,429,487, owned by Abcam.
MabIgG9E454Affinity Purified
100ul-20°CBlue IceRabbit
PEG with terminal methoxy group, conjugated to KLH.
Purified by Protein A affinity chromatography.
Supplied as a liquid, pH 7.4, 0.05% BSA, 0.01% sodium azide, 50% glycerol.
Recognizes the terminal methoxy group of the PEG molecule. Detects only conjugated forms of PEG. Does not crossreact with non-specific targets in blood or serum.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Guiotto, A. et al. (2004) Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg. Med.Chem. 12, 5031. 2. Wong, S.S. (1991) Reactive groups of proteins and their modifying agents. In Chemistry of protein conjugation and cross-linking, p. 13, CRC Press. 3. Caliceti, P. et al.(1993) Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J. Bioact. Comp. Polym. 8, 41. 4. Frank Leenders, celares GmbH, Berlin, Germany.(2006) PEGylation technology and biopharmaceuticals. Biopharmaceuticals. 6, 39-40. 5. Francesco M.Veronese, Gianfranco Pasut. (2005) PEGylation, successful approach.